Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

284858

Sigma-Aldrich

(−)-Norgestrel

98%

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H28O2
CAS-Nummer:
797-63-7
Molekulargewicht:
312.45
EG-Nummer:
212-349-8
MDL-Nummer:
MFCD00199013
UNSPSC-Code:
12352115
PubChem Substanz-ID:
24857181

Assay

98%

Optische Aktivität

[α]20/D −32°, c = 1 in chloroform

mp (Schmelzpunkt)

239-241 °C (lit.)

SMILES String

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(CC)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChIKey

WWYNJERNGUHSAO-XUDSTZEESA-N

Angaben zum Gen

human ... PGR(5241)
rat ... Ar(24208)

Anwendung

Produkt-Nr.
Beschreibung
Preisangaben

Ersetzt durch

Produkt-Nr.
Beschreibung
Preisangaben

N2260

D(−)-Norgestrel, analytical standard

Piktogramme

Health hazard
GHS08

Signalwort

Danger

Gefahreneinstufungen

Carc. 2 - Lact. - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Alice W Y Wong et al.
Obstetrics and gynecology, 121(5), 943-950 (2013-05-03)
To estimate the rate of endometrial pathology with the prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen. This was a randomized contro-lled trial of 129 Chinese women who attended a university hospital in Hong
Satu Heliövaara-Peippo et al.
American journal of obstetrics and gynecology, 209(6), 535-535 (2013-09-04)
Menorrhagia is a common problem impairing the quality of life (QOL) of many women. Both levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy are effective treatment modalities but no long-term comparative studies of QOL and costs exist. The objective of this study
Ioannis D Gallos et al.
Obstetrics and gynecology, 121(6), 1165-1171 (2013-07-03)
To identify predictors and to estimate their prognostic accuracy for regression and relapse of endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system or oral progestogens. This was a cohort study of women treated with levonorgestrel-releasing intrauterine system or oral progestogens for
Elizabeth A McCarthy et al.
Contraception, 86(5), 587-590 (2012-04-14)
Correctly placed levonorgestrel-releasing intrauterine systems (LNG-IUSs) are rarely associated with intrauterine pregnancy when pregnancy occurs. LNG-IUS retrieval, termination of pregnancy and conservative management if retracted strings prevent ready removal are the usual clinical options given to women. The conservative course
Anita Nelson et al.
Obstetrics and gynecology, 122(6), 1205-1213 (2013-11-19)
To evaluate the efficacy and safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel
Alle zugehörigen Dokumente anzeigen

Chromatograms

application for HPLC

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.